Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2025-12-24 @ 9:42 PM
NCT ID:
NCT00483132
Brief Summary:
Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).
Detailed Description:
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a
Study:
NCT00483132
Study Brief:
Protocol Section:
NCT00483132